drugset / Trial / NCT02420977
Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer
Phase 0
Completed
23 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This research is being done to see if an investigational radioactive imaging agent (radiotracer) called 18F-DCFPyL can help us find prostate cancer at its original site in the prostate gland and in distant sites (bone, lymph nodes) in men diagnosed with prostate cancer before surgery.
Timeline
- Start
- 2018-12-06
- Primary completion
- 2024-03-01
- Completion
- 2025-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DCFPyL | Small molecule | — | — |